Today we announced our half year results for the period ending 31 December 2025, which delivered strong financial performance. Underpinning the results were the continued expansion of Chemist Warehouse, and the integration of the two businesses which has already delivered business synergies.
“Our first half performance reinforces the strength of Sigma,” said Sigma CEO & MD Vikesh Ramsunder. “As an integrated healthcare business we see long-term opportunities for growth, headlined by sustained performance across our core domestic market, led by CW branded stores. This has continued to be a consistent feature of the CW business over the past two decades.”
As part of our results, we are reporting:
- Normalised EBIT of $582.9m, up 18.7% on the prior corresponding period (pcp)
- Normalised NPAT of $392.0m, up 19.2% on pcp
- Revenue of $5.5bn, up 14.9% on pcp
- Performance driven by Australian CW branded store sales up 17.2% with like-for-like (LFL) sales up 15.0%
- International growth accelerated, with retail network sales up 24.5% for the half, and LFL sales up 11.1%
- Net debt down $117.1m to $635.1m, equating to 0.6x normalised EBITDA, reflecting a strong and conservatively leveraged balance sheet
- Transformation and integration programs are tracking to plan.
Read the full ASX release and investor presentation.
Back
